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SynthesisAbstract In the present study, some pyrazolopyrimidin-6(7H)-ones and tricyclic 8-oxo-
dihydrooxazolopyrazolopyrimidin-9-ium chloride derivatives were synthesized and tested for
anti-inﬂammatory and analgesic activity and assessment of acute ulcerogenic propensity as com-
pared to the standard drug indomethacin. Some of the compounds (2c–2e; 3c–3e) showed apprecia-
ble anti-inﬂammatory–analgesic activity at the evaluated equimolar dose with lower ulcerogenic
proﬁle when compared with the standard. Compounds containing fused dihydrooxazolo ring (3e)
system were found to be more active than their corresponding congener pyrazolopyrimidine.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Non-steroidal anti-inﬂammatory drugs are one of the most
commonly prescribed medicines but due to gastrointestinal
side effects it impedes their use in long term therapy. Drugs
which are therapeutically active as well as safer in terms of gas-
tric tolerance are still the requirement of time to face the chal-
lenges of clinical therapy of gout and other inﬂammatorydisorders. Allopurinol, a well-known clinically approved drug
for gouty arthritis, is an excellent example of drug possessing a
fusion of the pyrimidine ring with a pyrazole nucleus. Fused
ring systems bearing pyrimidine nucleus have received wide-
spread attention during recent years on account of their
diverse mechanism of action and utilization as antinociceptive,
anti-inﬂammatory (Kowaluk et al., 2000), antiviral (Rashad
et al., 2008), hypnotic agents (George, 2001), in the treatment
of seizures, ischemia, neurodegeneration (Bauser et al., 2004;
Peat et al., 2004) and antimicrobial activity (Khobragade
et al., 2010). Among all the activities, efforts were directed
on the effectiveness of this fused ring system for the anti-
inﬂammatory and analgesic activity (Ugarkar et al., 2003).
Russo et al. (1992, 1993) ﬁrst reported the condensed planer
pyrazolotriazolopyrimidine and pyrazolothiazolopyrimidine
tricyclic ring systems that exhibited remarkable analgesic and)-ones
oi.org/
2 A. Kulshrestha et al.anti-inﬂammatory activity with signiﬁcant gastric tolerance.
Additionally, Alagarsamy et al. (2006) synthesized and evalu-
ated a series of fused tricyclic compounds having tetra-
hydrobenzothienopyrimidine nucleus and few of them
exhibited potent anti-inﬂammatory activity with better ulcer
index. Das et al. (2008b) suggest that the pyrazolopyrimidine
scaffold elicits their anti-inﬂammatory activities via selective
inhibition of mitogen activated protein kinase p38a. Activa-
tion of p38a leads to upregulation of pro-inﬂammatory cyto-
kines such as TNFa and IL-1b.
The present study deals with the synthesis and pharmaco-
logical evaluation of some 4-amino pyrazolopyrimidinones
(2a–2e) and its novel tricyclic dihydroxazolo derivatives (3a–
3e). All the compounds were synthesized according to
Scheme 1. The molecules were designed keeping in mind vari-
ous aspects involved in positional constrain and bioisosteric
replacement. The dihydroxazolo moiety has been inserted in
a lateral position (3a–3e) with an emphasis to attain maximum
anti-inﬂammatory–analgesic activity and circumventing the
problem of ulcerogenic potential. Further the N1 position of
all the designed molecules is substituted with an aromatic ring
in conformity with the pharmacophoric requirement of
extended lipophilicity (Russo et al., 1992).
2. Materials and methods
The reagents and solvents used in this study were of analytical
grade and procured from Sigma Aldrich (India) and indometh-
acin was obtained as a gift sample from Zydus Cadila Health-
care (India). The progress of the reactions were monitored by
thin layer chromatography developed with chloroform: ben-
zene (9:1) and chloroform: methanol (1:1) and performed on
Merck silica Gel 60 F254 aluminum sheets (Merck, Darms-
tadt, Germany) and products were recrystallized from appro-
priate solvents. Melting points were determined in open
capillaries using a Stuart SMP10 electrothermal melting point
apparatus and are uncorrected. IR spectra were recorded on a
Shimadzu 8300 FTIR spectrophotometer on KBr pellets and
mmax was recorded in cm
1. 1H NMR spectra were performed
on a JEOL AL300 FT-NMR (300 MHz) in DMSO using tet-
ramethylsilane as internal standard and the chemical shifts
were reported in ppm. Elemental analyses for C, H, and N
were performed on an Exeter CE-440 elemental analyzer.
2.1. General procedure for the synthesis of 5-amino-N-
substituted-1H-pyrazole-4-carbonitrile (1a–1e)
10 mmol of hydrazine hydrate and substituted phenyl hydra-
zine (prepared by diazotization of substituted anilines followed
by reduction with Na2SO3Æ7H2O) (Das et al., 2008a) were dis-
solved in 25 mL of ethanol in a round bottom ﬂask. 10 mmol
of ethoxymethylenemalononitrile (EMMN) was added to itC2H5O CH
C
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Scheme 1 Reagents and conditions: (a) R-NHNH2, ethanol, re
chloroacetamide, Et3N, toluene, reﬂux, 3 h; (ii) HCl.
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and the ﬁltrate evaporated in vacuo to yield the product fol-
lowed by recrystallization from methanol.
2.2. General procedure for the synthesis of 4-amino-1-
substituted-pyrazolo [3,4-d]pyrimidin-6(7H)-one (2a–2e)
0.01 mol of (1a–1e) was heated with 0.02 mol of urea at 180–
200 C until the clear melt becomes solid. Cooled solid was
then dissolved in 2 N NaOH and the solution was boiled with
charcoal for 10 min and ﬁltered. The boiling ﬁltrate was acid-
iﬁed with glacial acetic acid. This acidiﬁed solution was ﬁltered
hot to yield a tan colored product that was puriﬁed by dissolv-
ing small sample in boiling dilute NaOH and precipitating it
from hot solution of acetic acid. The procedure was repeated
to yield the pure compounds (Robins, 1956).
2.2.1. 4-Amino-1H-pyrazolo [3,4-d] pyrimidin-6(7H)-one (2a)
Yield 81% (Ethanol) 264–266 C; IR mmax (KBr, cm1): 1564
(AC‚N stretch), 1645 (AC‚O), 3254, 3384 (heteroaromatic 1
amine, NH stretch), 3439 (heterocyclic NH stretch). 1H-NMR
(300MHz, dH, DMSO): d 6.81 (2H, bs, Hb), d 7.58 (1H, s, Hc), d
7.79 (1H, s, Ha), d 8.10 (1H, s, Hd). Anal. Calcd. for C5H5N5O:
C, 39.74; H, 3.33; N, 46.34; Found C, 39.87; H, 3.29; N, 46.41.
2.2.2. 4-Amino-1-phenyl-1H-pyrazolo [3,4-d] pyrimidin-6(7H)-
one (2b)
Yield 76% (Ethanol); m.p. 271–273 C; IR mmax (KBr, cm1):
1183 (3 amine, CN stretch), 1528 (C‚N stretch), 1647
(C‚O), 3223, 3384 (heteroaromatic 1 amine, NH stretch),
3448 (heterocyclic NH stretch). 1H-NMR (300 MHz, dH,
DMSO): d 8.28 (1H, s, Ha), d 6.80 (2H, bs, Hb), d 8.07 (1H,
d, Hc), d 7.79–7.81(5H, m, Ar–H). Anal. Calcd. for
C11H9N5O: C, 58.14; H, 3.99; N, 30.82; Found C, 58.09; H,
3.75; N, 29.93.
2.2.3. 4-Amino-1-(4-nitrophenyl)-1H-pyrazolo [3,4-d]
pyrimidin-6(7H)-one (2c)
Yield 85% (Ethanol); m.p. 255–257 C; IR mmax (KBr, cm1):
1161 (3 amine, –CN stretch), 1560 (aromatic –NO2 asymmet-
ric stretch), 1594 (C‚N stretch), 1620 (C‚O), 3223, 3335
(heteroaromatic 1 amine, NH stretch), 3416 (heterocyclic
NH stretch). 1H-NMR (300 MHz, dH, DMSO): d 8.55 (1H,
s, Ha), d 6.81 (2H, bs, Hb), d 8.01 (1H, s, Hc), d 8.18 (2H,
d, Hd), d 8.45 (2H, d, He). Anal. Calcd. for C11H8N6O3: C,
48.53; H, 2.96; N, 30.87; Found C, 48.50; H, 2.93; N, 30.83.
2.2.4. 4-Amino-1-(4-chlorophenyl)-1H-pyrazolo [3,4-d]
pyrimidin-6 (7H)-one (2d)
Yield 64% (Ethanol); m.p. 285–286 C; IR mmax (KBr, cm1):
771 (C–Cl stretch), 1167 (3 amine, CN stretch), 1556 (C‚NN
N NR
N
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ﬂux, 3 h, (b) urea, 180–200 C, (c) (i) N-(4-bromophenyl)-2-
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NH stretch), 3437 (heterocyclic NH stretch). 1H-NMR
(300 MHz, dH, DMSO): d 8.10 (1H, s, Ha), d 6.85 (2H, bs,
Hb), d 7.98 (1H, s, Hc), d 7.50 (2H, d, Hd), d 7.66 (2H, d,
He). Anal. Calcd. for C11H8ClN5O: C, 50.49; H, 3.08 ; N,
26.76; Found C, 50.45; H, 3.04; N, 26.81.
2.2.5. 4-Amino-1-(2,4-dichlorophenyl)-1H-pyrazolo [3,4-d]
pyrimidin-6(7H)-one (2e)
Yield 72% (Ethanol); m.p. 269–270 C; IR mmax (KBr, cm1):
787 (C–Cl stretch), 1163 (3 amine, CN stretch), 1586 (C‚N
stretch), 1668 (C‚O), 3158, 3349 (heteroaromatic 1 amine,
NH stretch), 3437 (heterocyclic NH stretch). 1H-NMR
(300 MHz, dH, DMSO): d 8.09 (1H, s, Ha), d 6.85 (2H, bs,
Hb), d 7.96 (1H, s, Hc), d 7.54 (1H, s, Hd), d 7.34 (1H, d,
He), d 7.66 (1H, d, Hf). Anal. Calcd. for C11H7Cl2N5O: C,
44.62; H, 2.38 ; N, 23.65; Found C, 44.59; H, 2.36; N, 23.58.
2.3. General procedure for the synthesis of 4-amino-8-oxo-1-
substituted-7,8-dihydro-1H-oxazolo[3,2-a]pyrazolo[4,3-e]
pyrimidin-9-ium chloride (3a–3e)
A solution of 2 mmol of (2a–2e), 2 mmol N-(4-bromophenyl)-2-
chloroacetamide and 4 mmol triethylamine in 20 mL absolute
toluene was reﬂuxed for 3 h. Crystalline triethylamine was ﬁl-
tered off and washed with a small amount of benzene, which
was combined with the ﬁltrate. The mixture was treated with
HCl (10%) with constant stirring and evaporated. The residue
was washed with ice water, dried and recrystallized from propa-
nol–hexane (1:2) to give the ﬁnal dihydrooxazolo derivative of
pyrazolopyrimidin-9-ium chloride (Kulakov, 2009).
2.3.1. 4-Amino-8-oxo-7,8-dihydro-1H-oxazolo[3,2-a]
pyrazolo[4,3-e]pyrimidin-9-ium chloride (3a)
Yield 66% (DMSO); m.p. 102–104 C; IR mmax (KBr, cm1):
1070 (C–O–C), 1569 (C‚N stretch), 1732 (C‚O), 3158,
3349 (heteroaromatic 1 amine, NH stretch), 3437 (heterocy-
clic NH stretch). 1H-NMR (300 MHz, dH, DMSO): d 8.48
(1H, s, Ha), d 6.90 (2H, bs, Hb), d 4.64 (2H, s, Hc), d7.91
(1H, s, Hd). Anal. Calcd. for C7H6ClN5O2: C, 36.94; H,
2.66; N, 30.77; Found C, 37.01; H, 2.64; N, 30.83.
2.3.2. 4-Amino-8-oxo-1-phenyl-7,8-dihydro-1H-oxazolo[3,2-a]
pyrazolo[4,3-e]pyrimidin-9-ium chloride (3b)
Yield 75% (DMSO); m.p. 124–126 C; IR mmax (KBr, cm1):
1075 (C–O–C), 1226 (3 amine, CN stretch), 1593 (C‚N
stretch), 1731 (C‚O), 3248, 3342 (heteroaromatic 1 amine,
NH stretch), 3437 (heterocyclic NH stretch). 1H-NMR
(300 MHz, dH, DMSO): d 8.38 (1H, s, Ha), d 6.84 (2H, bs,
Hb), d 4.34 (2H, s, Hc), d 7.38–7.81 (5H, m, Ar–H). Anal.
Calcd. for C13H10ClN5O2: C, 51.41; H, 3.32; N, 23.06; Found
C, 51.54; H, 3.31; N 22.99.
2.3.3. 4-Amino-1-(4-nitrophenyl)-8-oxo-7,8-dihydro-1H-
oxazolo[3,2-a]pyrazolo[4,3-e]pyrimidin-9-ium chloride (3c)
Yield 62% (DMSO); m.p. 118–120 C; IR mmax (KBr, cm1):
1116 (C–O–C), 1210 (3 amine, CN stretch), 1541 (aromatic
–NO2 asymmetric stretch), 1583 (C‚N stretch), 1725
(C‚O), 3268, 3359 (heteroaromatic 1 amine, NH stretch),
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s, Hc), d 8.43 (2H, d, Hd), d 8.54 (2H, d, He). Anal. Calcd.
for C13H9ClN6O4: C, 49.69; H, 3.21; N, 26.74; Found C,
49.83; H, 3.22; N, 26.65.
2.3.4. 4-Amino-1-(4-chlorophenyl)-8-oxo-7,8-dihydro-1H-
oxazolo[3,2-a]pyrazolo[4,3-e]pyrimidin-9-ium chloride (3d)
Yield 59% (DMSO); m.p. 165–167 C; IR mmax (KBr, cm1):
763 (C–Cl stretch), 1081 (C–O–C), 1207 (3 amine CN stretch),
1587 (C‚N stretch), 1723 (C‚O), 3268, 3387 (heteroaromatic
1 amine, NH stretch), 3448 (heterocyclic NH stretch). 1H-
NMR (300 MHz, dH, DMSO): d 8.20 (1H, s, Ha), d 6.82
(2H, s, Hb), d 4.37 (2H, s, Hc), d 7.47 (2H, d, Hd), d7.55
(2H, d, He). Anal. Calcd. for C13H9Cl2N5O2: C, 46.17; H,
2.68; N, 20.71; Found C, 46.01; H, 2.67; N, 20.64.
2.3.5. 4-Amino-1-(2,4-dichlorophenyl)-8-oxo-7,8-dihydro-1H-
oxazolo[3,2-a]pyrazolo[4,3-e]pyrimidin-9-ium chloride (3e)
Yield 81% (DMSO);m.p. 198–200 C; IR mmax (KBr, cm1): 760
(C–Cl stretch), 1080 (C–O–C), 1195 (3 amine CN stretch), 1583
(C‚N stretch), 1720 (C‚O), 3248, 3368 (heteroaromatic 1
amine, NH stretch), 3426 (heterocyclic amine NH stretch). 1H-
NMR (300 MHz, dH, DMSO): d 8.31 (1H, s, Ha), d 6.53 (2H,
s, Hb), d 4.43 (2H, s, Hc), d 7.58 (1H, s, Hd), d 7.27 (1H, d,
He), d 7.63 (1H, d, Hf). Anal. Calcd. for C13H8Cl3N5O2: C,
41.91; H, 2.16; N, 18.80; Found C, 41.77 ; H, 2.15; N, 18.86.
2.4. Pharmacological evaluation
Healthy Charles Foster rats (150–200 g) and Swiss albino mice
(20–25 g) of either sex were procured from animal house, Insti-
tute ofMedical Science, BanarasHinduUniversity for the activ-
ity studies. The animals were housed in Perspex cages under
standard conditions of temperature (24 ± 1 C) and relative
humidity (65 ± 10%) with free access to standard pellet diet
and water ad libitum. All the animals were randomly distributed
into groups of six each. Animals were allowed to acclimatize for
seven days to their environment before experimentation. The
experimental protocol was approved by the Institutional Ani-
mal Ethical Committee (IAEC) [Approval No. Dean/10–11/
61], Institute of Medical Sciences, Banaras Hindu University.
Experiments were conducted following the guidelines issued
by the National Institute of Health (NIH) for the care and use
of laboratory animals. All the synthesized derivatives (2a–2e)
and (3a–3e) were evaluated for anti-inﬂammatory and analgesic
activity along with an assessment of their ulcerogenic liability.
2.5. Determination of acute toxicity
The acute toxicity determination for the synthesized deriva-
tives was carried out as per OECD guidelines (OECD 423-
2002) on healthy albino mice of either sex.
2.6. Anti-inﬂammatory activity
2.6.1. Carrageenan induced rat paw edema
Rats (n= 6) were fasted overnight and allowed free access to
water ad libitum. Left paw was marked with ink at the level of
lateral malleolus and the total increase in edema volume is
measured by the mercury displacement technique with the helpnd pharmacological evaluation of some pyrazolopyrimidin-6(7H)-ones
rivatives. Arabian Journal of Chemistry (2014), http://dx.doi.org/
4 A. Kulshrestha et al.of plethysmometer (UGO Basile, Italy) at 1, 2, 3, 4, 5 and 6 h
after carrageenan treatment. The animals of Group I (control
group) were administered 1% carboxy methyl cellulose
(10 mL/kg, p.o.), animals of Group II (standard) were admin-
istered indomethacin (10 mg/kg p.o.) whereas animals of all
other groups were administered the synthesized test com-
pounds (2a–2e; 3a–3e) in an equimolar dose relative to
10 mg/kg of indomethacin. One hour after dosing, the rats
were challenged by a subcutaneous injection of 0.1 mL of
1% solution of carrageenan into the sub-plantar side of the left
hind paw. The total edema volume as compared to basal vol-
ume was measured at 1, 2, 3, 4, 5 and 6 h after the carrageenan
injection. The increase in the edema volume was calculated at
each interval and evaluated statistically (Vogel, 2002).
The percent inhibition of inﬂammation was calculated
using the formula as follows:
% Inhibition ¼ ðEc Et=EcÞ  100
Ec =Mean of edema volume of the control group.
Et =Mean of edema volume of the test group.
2.6.2. Acute ulcerogenic activity
Ulcerogenic activity was evaluated after p.o. administration of
test compounds or indomethacin at the dose of 10 mg/kg.
Control rats received p.o. administration of vehicle (suspension
of 1% carboxy methyl cellulose). Food but not water was
removed 24 h before administration of the test compounds.
Twenty-four hours after the dosing, rats under deep ether
anesthesia were sacriﬁced so that the stomach could be
removed, opened along the curvature, washed with distilled
water and cleaned gently by dipping in saline. Stomach sam-
ples of all the groups obtained from ulcerated rats were ﬁxed
in 10% formalin which was embedded in parafﬁn blocks for
sectioning. The obtained sections (1–3 mm) were stained with
hematoxylin and eosin dye and ﬁnally monitored and photo-
graphed using a Nikon digital microscope (Eclipse 200) at
10· magniﬁcation (Figs. 1a–3) (Hafez et al., 2010).
2.7. Analgesic activity
2.7.1. Acetic acid induced writhing in mice (Koster et al., 1959)
Mice were subjected to overnight fasting with provision for
water ad libitum and were divided into different groups eachFigure 1 (a) Histopathology: Rat’s stomach of the control grou
development of ulcers as indicated by disruption of epithelium.
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sodium CMC (control, 10 mL/kg, p.o.) and indomethacin
(10 mg/kg p.o.) as reference standards and test compounds
(2c–2e; 3c–3e) at an equimolar dose relative to 10 mg/kg of
indomethacin respectively. The number of writhing episodes
was counted for 30 min following (0.6% v/v) acetic acid injec-
tion. A signiﬁcant reduction in the number of writhing by any
treatment as compared to the number of writhing in control
animals was considered a positive analgesic response. The
analgesic activity was expressed as a percentage change from
writhing controls.2.7.2. Formalin-induced paw edema bioassay
The analgesic effect was also evaluated by this sub-acute
model. Mice were fasted overnight and provided water ad libi-
tum and were divided into different groups of 6 animals each.
After administration of, subplantar route of formalin
0.02 mL (1%), the time (seconds) which each mouse spent
licking was observed. Mice within the control group were
administered with 0.5% sodium CMC (10 mL/kg, p.o.), pen-
tazocin (10 mg/kg, i.p.) and indomethacin (10 mg/kg p.o.)
were used as reference standards and test compounds (2c–
2e; 3c–3e) at an equimolar dose relative to 10 mg/kg of pen-
tazocin and indomethacin, respectively. Time spent in licking
the injected paw was counted, and was considered as indica-
tive of pain. First the nociceptive response normally peaked
5 min after formalin injection and the second phase 15–
30 min after formalin injection, representing the neurogenic
and inﬂammatory pain responses, respectively (Hunskaar
and Hole, 1987). Mice were pretreated with reference stan-
dards and the test compounds 1 h before being challenged
with buffered formalin, and the responses were observed for
30 min.
2.8. Statistical analysis
All values are expressed as mean ± standard error of the
mean (SEM) for ‘n’ number of observations, where ‘n’ repre-
sents number of animals being studied. The results were ana-
lyzed by one way analysis of variance (ANOVA) followed by
Dunnett’s test. ‘p’ values more than 0.05 was considered as
non-signiﬁcant, less than 0.05 as signiﬁcant and less than
0.01 as extremely signiﬁcant as compared with the control
group.p showing intact epithelium. (b) Indomethacin group showing
nd pharmacological evaluation of some pyrazolopyrimidin-6(7H)-ones
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Figure 2 (a) Histopathology: Rat’s stomach of test compound (3e) indicating minimal ulcer (33.3%). (b) Intact mucosa of control group.
Figure 3 Indomethacin showing mucosal bleeding.
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3.1. Chemistry
Proposed derivatives have been synthesized according to
Scheme 1 starting from EMMN. The structures of the com-
pounds obtained were supported by spectroscopic measure-
ments and elemental analysis. The FT-IR spectra of 2a–2e
and 3a–3e showed two characteristic stretchings of primary
amine at around 3158–3349 cm1 and 3158–3387 cm1 respec-
tively. A peak at around 1620–1668 cm1 and 1720–1732 cm1
is attributed to the presence of –C‚O in pyrimidine nucleus
and dihydrooxazolo moiety of 2a–2e and 3a–3e respectively.
Further, all the derivatives showed diagnostic IR absorptions
at 1528–1594 cm1 stretching for –C‚N in the pyrazole
nucleus. Additional peak at 1070–1116 cm1 conﬁrmed C–
O–C stretching in dihydrooxazolo ring system of 3a–3e.
1H-NMR spectra of all the derivatives showed a peak
within the range of d 7.79–8.55 corresponding to –CH (Ha)
proton of pyrazole nucleus. The free –NH2 protons appear
as broad singlet with a corresponding chemical shift value in
the range of d 6.53–6.90. The –NH proton (Hc) of pyrimidine
nucleus (2a–2e) displayed singlet signal in the range of d 7.78–
8.07 while the secondary N1 proton of unsubstituted deriva-
tives (2a and 3a) showed singlet at 8.10 and 7.91 respectively.Please cite this article in press as: Kulshrestha, A. et al., Design, synthesis a
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presence of Hc methylene protons which appears as singlet
at around d 4.34–4.74. All the other protons belonging to
the N1 substituted phenyl ring were seen according to the
expected chemical shift. The elemental analysis results were
within ±0.4% of the theoretical values.
3.2. Pharmacology
In post-acute toxicity studies, the synthesized derivatives (2a–
2e; 3a–3e) were evaluated by the carrageenan induced rat
paw edema method as described by Winter et al. (1962) fol-
lowed by the evaluation of their ulcerogenic liability (Table 1).
Carrageenan induced paw edema model was used to evalu-
ate the effects of acute inﬂammation. Carrageenan is a mixture
of polysaccharides composed of sulfated galactose units and it
is derived from Irish Sea moss, Chondrous crispus. The time
course of edema development in carrageenan-induced paw
edema model in rats is generally represented by a biphasic
curve. The early or the ﬁrst phase of inﬂammation occurs after
an hour of carrageenan injection and is partly attributed to
trauma of injection and also to histamine, and serotonin com-
ponents. The late or the second phase (after 3 h of carrageenan
injection) is associated with the production of bradykinin, pro-
tease, prostaglandin, and lysosome (Vinegar et al., 1969).
The anti-inﬂammatory activity of synthesized derivatives
was assessed from their ability to inhibit the paw edema
induced by carrageenan in rats. The tested compounds exhib-
ited anti-inﬂammatory activity spanning over a range from
53.46% to 89.06% as compared to 90.15% inhibition by stan-
dard drug indomethacin after 6 h.
The anti-inﬂammatory effects of the 4-amino-8-oxo-1-
substituted-7,8-dihydro-1H-oxazolo[3,2-a]pyrazolo[4,3-e]pyr-
imidin-9-ium chloride derivatives (3a–3e) were found to be
greater than those of 4-amino-1-substituted-pyrazolo [3,
4-d]pyrimidin-6(7H)-one intermediate (2a–2e). After 6 h of
carrageenan administration, compound 3e exhibited maxi-
mum anti-inﬂammatory effect (89.06%), followed by 3c and
3d with 85.66% and 82.26% inhibition respectively among
the derivatives (3a–3e). Similarly, among derivatives (2a–
2e), 2e exerted maximum anti-inﬂammatory effect (77.15%)
closely followed by derivative 2d (76.54%) and derivative 2c
(72.90% respectively). Rest of the derivatives exhibited mod-
erate to weak anti-inﬂammatory activity. The above results
reafﬁrm our belief that the dihydroxazolo moiety which hasnd pharmacological evaluation of some pyrazolopyrimidin-6(7H)-ones
rivatives. Arabian Journal of Chemistry (2014), http://dx.doi.org/
T
a
b
le
1
E
ff
ec
t
o
f
th
e
sy
n
th
es
iz
ed
co
m
p
o
u
n
d
s
(2
a
–
3
e)
o
n
ca
rr
a
g
ee
n
a
n
in
d
u
ce
d
ra
t
p
a
w
ed
em
a
v
o
lu
m
e.
C
o
m
p
(n
=
6
)
E
d
em
a
v
o
lu
m
e
(m
L
)
m
ea
n
±
S
E
M
(%
in
h
ib
it
io
n
)
%
a
n
im
a
ls
w
it
h
u
lc
er
s
6
0
m
in
1
2
0
m
in
1
8
0
m
in
2
4
0
m
in
3
0
0
m
in
3
6
0
m
in
C
o
n
tr
o
l
0
.5
6
6
±
0
.0
1
7
0
.6
2
1
±
0
.0
1
1
0
.6
8
8
±
0
.0
1
1
0
.7
7
0
±
0
.0
1
4
0
.8
1
5
±
0
.0
0
8
0
.8
2
3
±
0
.0
1
1
–
In
d
o
0
.2
1
6
±
0
.0
9
6
(6
1
.8
3
)
0
.1
6
3
±
0
.0
9
1
(7
3
.7
5
)
0
.1
4
3
±
0
.0
5
1
*
(7
9
.2
1
)
0
.1
0
6
±
0
.0
2
0
*
*
(8
6
.2
3
)
0
.0
7
0
±
0
.0
1
7
*
*
(9
1
.4
1
)
0
.0
8
1
±
0
.0
2
0
*
*
(9
0
.1
5
)
5
/6
(8
3
.3
)
2
a
0
.4
4
5
±
0
.0
9
9
(2
1
.3
7
)
0
.4
3
5
±
0
.0
9
7
(2
9
.9
5
)
0
.4
2
0
±
0
.0
8
6
(3
8
.9
5
)
0
.4
1
8
±
0
.1
0
6
(4
5
.7
1
)
0
.3
9
5
±
0
.0
9
3
(5
1
.5
3
)
0
.3
8
3
±
0
.0
9
8
(5
3
.4
6
)
1
/6
(1
6
.6
)
2
b
0
.4
1
0
±
0
.1
1
3
(2
7
.5
6
)
0
.4
0
5
±
0
.1
0
0
(3
4
.7
8
)
0
.3
8
0
±
0
.1
0
9
(4
4
.7
6
)
0
.3
5
8
±
0
.0
9
9
(5
3
.5
0
)
0
.3
1
5
±
0
.0
8
6
(6
1
.3
4
)
0
.3
3
1
.±
0
.0
9
3
(5
9
.7
8
)
1
/6
(1
6
.6
)
2
c
0
.3
4
5
±
0
.1
0
5
(3
0
.0
4
)
0
.3
0
8
±
0
.1
0
3
(5
0
.4
0
)
0
.2
7
6
±
0
.1
0
0
(5
9
.8
8
)
0
.2
4
6
±
0
.0
6
2
*
(6
8
.0
5
)
0
.1
9
5
±
0
.0
5
4
*
(7
6
.0
7
)
0
.2
2
3
±
0
.0
5
9
*
(7
2
.9
0
)
3
/6
(5
0
.0
)
2
d
0
.3
2
8
±
0
.1
0
6
(4
2
.0
4
)
0
.2
9
6
±
0
.1
0
6
(5
2
.3
3
)
0
.2
7
1
±
0
.0
8
9
(6
0
.6
1
)
0
.2
3
1
±
0
.0
6
0
*
(7
0
.0
0
)
0
.1
8
1
±
0
.0
1
5
*
*
(7
7
.7
9
)
0
.1
9
3
±
0
.0
5
5
*
(7
6
.5
4
)
4
/6
(6
6
.6
)
2
e
0
.3
2
5
±
0
.1
0
8
(4
2
.5
7
)
0
.2
6
8
±
0
.1
0
1
(5
6
.8
4
)
0
.2
5
3
±
0
.0
5
7
*
(6
3
.2
2
)
0
.2
1
0
±
0
.0
5
8
*
(7
2
.7
2
)
0
.1
6
0
±
0
.0
1
4
*
*
(8
0
.3
6
)
0
.1
8
8
.±
0
.0
1
7
*
*
(7
7
.1
5
)
3
/6
(5
0
.0
)
3
a
0
.3
8
8
±
0
.1
2
0
(3
1
.4
4
)
0
.3
8
0
±
0
.1
1
2
(3
8
.8
0
)
0
.3
5
5
±
0
.1
0
9
(4
8
.4
0
)
0
.3
3
8
±
0
.1
1
7
(5
6
.1
0
)
0
.2
7
0
±
0
.1
0
0
(6
6
.8
7
)
0
.2
8
5
±
0
.1
0
6
(6
5
.3
7
)
1
/6
(1
6
.6
)
3
b
0
.3
7
0
±
0
.1
1
5
(3
4
.6
2
)
0
.3
4
8
±
0
.1
1
0
(4
3
.9
6
)
0
.3
3
5
±
0
.1
0
5
(5
1
.3
0
)
0
.2
9
8
±
0
.0
9
9
(6
1
.2
9
)
0
.2
3
5
±
0
.0
5
5
*
(7
1
.1
6
)
0
.2
4
8
±
0
.0
5
8
*
(6
9
.8
6
)
2
/6
(3
3
.3
)
3
c
0
.2
8
1
±
0
.1
0
6
(5
0
.3
5
)
0
.2
2
5
±
0
.1
0
2
(6
3
.7
6
)
0
.1
9
8
±
0
.0
1
5
*
(7
1
.2
2
)
0
.1
6
5
±
0
.0
1
9
*
*
(7
8
.5
7
)
0
.0
9
8
±
0
.0
1
6
*
*
(8
7
.9
7
)
0
.1
1
8
.±
0
.0
1
8
*
*
(8
5
.6
6
)
3
/6
(5
0
.0
)
3
d
0
.3
1
1
±
0
.1
0
4
(4
5
.0
5
)
0
.2
5
1
±
0
.1
0
7
(5
9
.5
8
)
0
.2
2
0
±
0
.0
1
8
*
(6
8
.0
2
)
0
.1
6
8
±
0
.0
2
2
*
*
(7
8
.1
8
)
0
.1
2
8
±
0
.0
1
7
*
*
(8
4
.2
9
)
0
.1
4
6
±
0
.0
0
7
*
*
(8
2
.2
6
)
4
/6
(6
6
.6
)
3
e
0
.2
8
6
±
0
.1
0
2
(4
9
.4
6
)
0
.2
2
3
±
0
.1
0
7
(6
4
.0
9
)
0
.1
9
3
±
0
.0
5
5
*
(7
1
.9
4
)
0
.1
4
1
±
0
.0
2
0
*
*
(8
1
.6
8
)
0
.0
9
6
±
0
.0
1
6
*
*
(8
8
.2
2
)
0
.0
9
0
±
0
.0
1
9
*
*
(8
9
.0
6
)
2
/6
(3
3
.3
)
E
a
ch
v
a
lu
e
is
th
e
m
ea
n
±
S
E
M
o
f
6
ra
ts
.
p
<
0
.0
1
*
*
,
p
<
0
.0
5
*
co
m
p
a
re
d
w
it
h
co
n
tr
o
l,
st
a
ti
st
ic
a
l
a
n
a
ly
si
s
b
y
o
n
e
w
a
y
A
N
O
V
A
fo
ll
o
w
ed
b
y
D
u
n
n
et
t’
s
te
st
.
C
o
n
tr
o
l:
0
.5
%
so
d
iu
m
C
M
C
so
lu
ti
o
n
in
d
is
ti
ll
ed
w
a
te
r
(1
0
m
L
/k
g
p
.o
.)
.
In
d
o
:
R
ef
er
en
ce
st
a
n
d
a
rd
in
d
o
m
et
h
a
ci
n
(1
0
m
g
/k
g
p
.o
.)
.
V
a
lu
es
in
b
o
ld
in
d
ic
a
te
m
o
d
er
a
te
to
si
g
n
iﬁ
ca
n
t
%
in
h
ib
it
io
n
co
m
p
a
ra
b
le
to
st
a
n
d
a
rd
.
6 A. Kulshrestha et al.
Please cite this article in press as: Kulshrestha, A. et al., Design, synthesis an
and tricyclic 8-oxo-dihydrooxazolopyrazolopyrimidin-9-ium chloride der
10.1016/j.arabjc.2014.03.012been inserted in a lateral position (3a–3e) is responsible for
further improving the anti-inﬂammatory effect as compared
to its corresponding 4-amino pyrazolopyrimidinone inter-
mediates (2a–2e). Also, it might be stated that the synthe-
sized derivatives exhibit their anti-inﬂammatory effect
through the prostaglandin mediated mechanism as they
seem to be more effective in the second phase of carra-
geenan-induced edema as compared to the early phase.
The ulcerogenic liabilities of compounds (2a–2e; 3a–3e) were
signiﬁcantly less than that of indomethacin at the observed
equimolar dose level. The 2,4-dichlorophenyl substitution
at N1 position of pyrazolopyrimidine has considerably
enhanced the anti-inﬂammatory activity proﬁle of both 2e
and 3e. From the obtained results as reported in Table 1,
it has been noticed that all the synthesized derivatives exhib-
ited reduced ulcerogenicity (16.6–66.6%) (Fig. 2b) and are
considered to be safer than indomethacin which exhibited
an ulcerogenic liability of 83.3% (Fig. 1b).
Derivatives (2c–2e) and (3c–3e) which displayed compa-
rable anti-inﬂammatory activity with reduced ulcerogenicity
were further evaluated for analgesic activity employing ace-
tic acid induced writhing in mice and formalin induced paw
edema in mice. Acetic acid is postulated to induce pain by
increasing ﬂuids comprising of PGE2 and PGF2a
(Deraedt et al., 1980) at the peritoneal receptors. Acetic acid
acts indirectly by inducing the release of endogenous
mediators, which is responsible for the stimulation of the
nociceptive neurons that are sensitive to non-steroidal
anti-inﬂammatory drugs and narcotics (Bentley et al.,
1983; Collier et al., 1968). In the acetic acid induced writh-
ing test the analgesic activity of the derivatives is expressed
as ‘‘mean increase in latency after drug administra-
tion ± SEM’’ relative to control and percentage inhibition
in writhing reﬂex. Among the evaluated derivatives at an
equimolar oral dose of 10 mg/kg indomethacin, derivative
3e exhibited maximum inhibition of writhings (70.48%) fol-
lowed by derivatives 3d, 3c, 2e, 2d and 2c as compared to
78.22% inhibition of writhing by indomethacin. Surpris-
ingly, the overall results suggest that probably the dihydrox-
azolo moiety (3c–3e) accentuates the analgesic proﬁle of the
derivatives as compared to their corresponding 4-amino pyr-
azolopyrimidinone intermediates (2c–2e).
The formalin-induced pain test consists of two distinct
periods of response, i.e. early (tonic pain) and late phase
(inﬂammatory pain) response. The response is evaluated by
counting the time spent with licking and elevation (lifting)
of the injected paw, ﬂinching, and also protection of the
paw from full pressure when walking or resting (Porro and
Cavazzuti, 1993) Drugs that act primarily on the CNS inhibit
both phases equally while peripherally acting drugs inhibit
the late phase (Tjolsen et al., 1992). The formalin test assesses
the behavioral response to injection of dilute formation into
the paw of an animal. In the formalin test, pretreatment of
mice with the derivatives (2c–2e; 3c–3e) at equimolar doses
of 10 mg/kg of standard drugs indomethacin and pentazocin
had a signiﬁcant effect during the second phase (15–30 min)
as can be seen from the data reported in Table 2 except that
derivative 2c did not have any signiﬁcant activity at both the
phases. The results obtained clearly indicate that the active
analgesic principal of the evaluated derivatives is acting
peripherally and not through mechanisms involving the cen-
tral nervous system.d pharmacological evaluation of some pyrazolopyrimidin-6(7H)-ones
ivatives. Arabian Journal of Chemistry (2014), http://dx.doi.org/
Table 2 Acetic acid writhing and formalin tests in mice.
Compound (n= 6) Total No. of writhings
(Mean ± SEM) (% inhibition)
Time spent with licking (sec) (Mean ± SEM) (% inhibition)
Phase I (0–10 min) Phase II (15–30 min)
Control 37.2 ± 0.092 155.8 ± 0.103 128.0 ± 0.112
Indomethacin 10 mg/kg p.o 8.10 ± 0.098** (78.22) 114.41 ± 0.142* (26.56) 62.38 ± 0.120** (51.26)
Pentazocine 10 mg/kg i.p – 73.66 ± 0.109**(52.72) 49.23 ± 0.117** (61.53)
2c 17.12 ± 0.135 *(53.97) 131.69 ± 0.198(15.47) 93.15 ± 0.213(27.22)
2d 16.29 ± 0.139* (56.20) 136.92 ± 1.189(12.11) 82.81 ± 0.160* (35.30)
2e 15.63 ± 0.135* (57.98) 130.95 ± 0.210(15.94) 77.30 ± 0.152* (39.60)
3c 14.32 ± 0.129* (61.50) 135.24 ± 0.202(13.19) 70.52 ± 0.119**(44.90)
3d 12.44 ± 0.100** (66.55) 127.06 ± 0.143* (18.44) 69.12 ± 0.115**(46.00)
3e 10.98 ± 0.097** (70.48) 122.95 ± 0.150* (21.08) 64.80±.120**(49.37)
Each value is the mean ± SEM of 6 mice.
<0.01**, p< 0.05* compared with control, statistical analysis by one way ANOVA followed by Dunnett’s test.
Control: 0.5% sodium CMC solution in distilled water (10 mL/kg p.o.).
Values in bold indicate moderate to signiﬁcant % inhibition comparable to standard.
Synthesis and evaluation of some pyrazolopyrimidin-6(7H)-onesderivatives 74. Conclusion
In conclusion, we have identiﬁed a few pyrazolopyrimidin-
6(7H)-ones and novel tricyclic 8-oxo-dihydrooxazolopyrazolo-
pyrimidin-9-ium chloride derivatives having anti-inﬂammatory
and analgesic activity with considerable reduction in ulcero-
genic liabilities. Based on the comprehensive pharmacological
studies, the dihydrooxazolo moiety showed signiﬁcant aug-
mentation of activity as compared to pyrazolopyrimidin-
6(7H)-one. Further, there is potential scope for the newly
designed tricyclic 8-oxo-dihydrooxazolopyrazolopyrimidin-9-
ium molecules for further optimization.
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